Senior Medical Director
Adaptimmune
Dr. Michael J. Nathenson is a medical oncologist with specalization in soft tissue sarcomas. His experience includes a sarcoma medical oncology felllowship at MDACC, and 5 years treating sarcoma patients at the DFCI as well as participanting and conducting clincial trials in soft tissue sarcomas. Specifically he was responsible for the design and conduct of the phase II eribulin/pembrolizumab trial in LMS, LPS, and UPS/other sarcomas. More recently he has expierence as a medical director and senior medical director at GSK and then at Adaptimmune on engineered cell therapy trials.
